Lancet Infect Dis 2005,5(9):558–567 PubMedCrossRef 2 Eassa S, Ei

Lancet Infect Dis 2005,5(9):558–567.PubMedCrossRef 2. Eassa S, Eissa M, Sharaf SM, Ibrahim MH, Hassanein OM: Prevalence of hepatitis C virus infection and evaluation of a health education program in el-ghar village in zagazig, egypt. J Egypt Public Health Assoc 2007,82(5–6):379–404.PubMed 3. AbdulQawi K, Youssef NCT-501 chemical structure A, Metwally MA, Ragih I, AbdulHamid M, Shaheen A: Prospective study of prevalence and risk factors for hepatitis C in pregnant Egyptian women and its transmission to their infants. Croat Med J 2010,51(3):219–228.PubMedCrossRef 4. El-Karaksy HM, Anwar G, Esmat G, Mansour S, Sabry M, Helmy H, El-Hennawy

A, Fouad H: Prevalence of hepatic abnormalities in a cohort of Egyptian children with type 1 diabetes mellitus. Pediatr Diabetes 2009,1(7):462–70. 5. Fischer R, Baumert T, Blum HE: Hepatitis C virus infection and apoptosis. World J Gastroenterol 2007,13(36):4865–4872.PubMed 6. Mankouri J, Dallas ML, Hughes ME, Griffin SD, Macdonald A, Peers C, Harris M: Suppression of a pro-apoptotic K+ channel as a mechanism for hepatitis selleck compound C virus persistence. Proc

Natl Acad Sci USA 2009,106(37):15903–15908.PubMedCrossRef 7. Shin EC, Shin JS, Park JH, Kim JJ, Kim H, Kim SJ: Expression of Fas-related genes in human hepatocellular carcinomas. Cancer Lett 1998,134(2):155–162.PubMedCrossRef 8. Pitot HC: The molecular biology of carcinogenesis. Cancer 1993,72(3 Suppl):962–970.PubMedCrossRef 9. Kumar S: Caspase function in programmed cell death. Cell Death Differ 2007,14(1):32–43.PubMedCrossRef 10. Machida K, Tsukamoto H, Liu JC, Han YP, Govindarajan S, Lai selleck products MM, Akira S, Ou JH: c-Jun mediates hepatitis C virus hepatocarcinogenesis through signal transducer and activator of transcription 3 and nitric oxide-dependent impairment of oxidative DNA repair. Hepatology 2010,52(2):480–492.PubMedCrossRef 11. Panasiuk A, Parfieniuk A, Zak J, Flisiak R: Association among Fas expression in leucocytes, serum Fas and Fas-ligand concentrations and hepatic inflammation and fibrosis in chronic hepatitis C. Liver Int 2010,30(3):472–478.PubMedCrossRef 12. Basu A, Saito K, Meyer K, Ray RB, Friedman

SL, Chang YH, Ray R: Stellate cell apoptosis by a soluble mediator from immortalized human hepatocytes. Apoptosis 2006,11(8):1391–1400.PubMedCrossRef 13. Rokhlin OW, Bishop GA, Hostager BS, Waldschmidt TJ, Sidorenko SP, Pavloff N, Kiefer MC, Umansky SR, Glover RA, Cohen MB: Fas-mediated apoptosis in human prostatic carcinoma cell lines. Cancer Res 1997,57(9):1758–1768.PubMed 14. Brenner C, Grimm S: The permeability transition pore complex in cancer cell death. Oncogene 2006,25(34):4744–4756.PubMedCrossRef 15. Calabrese F, Pontisso P, Pettenazzo E, Benvegnu L, Vario A, Chemello L, Alberti A, Valente M: Liver cell apoptosis in chronic hepatitis C correlates with selleck inhibitor histological but not biochemical activity or serum HCV-RNA levels. Hepatology 2000,31(5):1153–1159.PubMedCrossRef 16.

Comments are closed.